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Summary
Hereditary spastic paraplegia (HSP) comprises a group
of clinically and genetically heterogeneous disorders
causing progressive spasticity and weakness of the lower
limbs. We report a large family of French descent with
autosomal dominant pure HSP. We excluded genetic
linkage to the known loci causing HSP and performed
a genomewide search. We found evidence for linkage of
the disorder to polymorphic markers on chromosome
2q24-q34: a maximum LOD score of 3.03 was obtained
for marker D2S2318. By comparison with families hav-
ing linkage to the major locus of pure autosomal dom-
inant HSP (SPG4 on chromosome 2p), there were sig-
nificantly more patients without Babinski signs, with
increased reflexes in the upper limbs, and with severe
functional handicaps.
Hereditary spastic paraplegia (HSP) comprises a group
of clinically and genetically heterogeneous disorders
causing progressive spasticity and weakness of the lower
limbs. The disease is characterized pathologically by ax-
onal degeneration in the long ascending and descending
tracts of the spinal cord, especially in their terminal por-
tions (Behan and Maia 1974). The corticospinal tracts
are mainly affected, but the columns of Goll and the
spinocerebellar tracts are also involved. HSPs are clas-
sified according to (1) the mode of inheritance (auto-
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somal dominant, autosomal recessive, or X linked) and
(2) the neurological or nonneurological signs associated
with spastic paraplegia (Harding 1981; Fink 1997). In
the pure form of HSP, in addition to pyramidal signs,
in the lower limbs, which dominate the clinical picture,
sphincter disturbances and diminished vibration sense
are frequently observed (Harding 1981; Polo et al. 1993;
Du¨rr et al. 1994; Fontaine et al. 1995). The so-called
complex forms of HSP are defined by the association of
spastic paraplegia with peripheral neuropathy, epilepsy,
extrapyramidal disturbances, ataxia, dementia, skin le-
sions, optic neuropathy, retinopathy, and deafness.
At least 11 different loci—SPG1–SPG11—have been
described as being involved in HSP (MIM 182600,MIM
182601, MIM 270800, MIM 312900, MIM 312920,
MIM 600363, MIM 601162 MIM 602783, and MIM
603563 (McKusick 1990; Martinez Murillo et al. 1999;
Reid et al. 1999); however, only genes encoding for
SPG1, SPG2, SPG4, and SPG7 have been identified.
SPG1 and SPG2 have been assigned to chromosome
regions Xq28 and Xq22, respectively. SPG2 is caused by
mutations in the proteolipid protein and is an allelic
variant of Pelizaeus-Merzbacher disease (Saugier-Veber
et al. 1994). SPG1 results frommutations in the L1CAM
gene and represents an incomplete form of the mental
retardation, aphasia, shuffling gait, and adducted
thumbs (MASA) syndrome (Jouet et al. 1994). Paraple-
gin is a mitochondrial metalloprotease encoded by
SPG7, located on chromosome 16q. Mutations in par-
aplegin have been shown to cause both pure and com-
plex forms of HSP with optic, cerebral, and cerebellar
atrophy of autosomal recessive inheritance (Casari et al.
1998). Spastin is a member of the AAA family (members
of which are ATPases associated with diverse cellular
activities) and is encoded by SPG4, located on chro-
mosome 2p. Mutations in spastin have been shown to
cause autosomal dominant HSP (Hazan et al. 1999).
Figure 1 Pedigree of family SAL-612. Affected individuals are indicated by blackened symbols. The haplotype segregating with the disease is boxed. Recombination events are noted by an
arrow. Reconstructed genotypes are in parentheses. The hatched symbols represent individuals considered, for purposes of LOD-score calculations, to be of undetermined clinical status: patient II:5
in family SAL-612, who, on the basis of her medical history, was considered to be affected but who was never examined by one of us; and individual III:5, who was 50 years old and who had
increased and spread reflexes in the lower limbs and an extensor plantar response (by Babinski sign) but no spasticity.
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Table 1
Clinical Characteristics of Family SAL-612 and Comparison with Individuals with Linkage to SPG4
Characteristic Family SAL-612 Individuals with SPG4 Pa
No. of patients (no. unaware of symptoms) 9 (2) 83 (23)
Mean age at onset (years) (17-68)39 16 (2-63)29 15 NS
Mean age at examination (years) (20-76)52 18 (3-85)45 20
Clinical signs present:b
Severe functional handicap 44% (4/9) 11% (9/83) !.05
Bilateral extensor plantar reflexes 56% (5/9) 88% (68/77) !.05
Increased and spread reflexes in lower limbs 67% (6/9) 94% (78/83) NS
Increased reflexes present in upper limbs 67% (6/9) 22% (18/83) !.05
Decreased vibration sense 77% (7/9) 56% (45/81) NS
Urinary urgency 14% (1/7) 34% (28/81) NS
Pes cavus or scoliosis 0% (0/9) 12% (10/79) NS
a NS = not significant.
b Comparison of clinical features in family SAL-612 versus those in families linked to SPG4 was as
described in the text.
In this study, we report a large family with autosomal
dominant pure spastic paraplegia. We excluded linkage
to known HSP loci at the beginning of our study and
performed a genomewide screen for a new HSP locus.
We found significant linkage between the disorder and
dinucleotide repeats in the chromosome 2q region.
The clinical inclusion criteria for the patients, prior to
the linkage study, were the existence of progressive spas-
tic paraplegia with pyramidal signs in the lower limbs
and, in the family overall, a disease segregation pattern
compatible with autosomal dominant inheritance (Du¨rr
et al. 1994, 1996). Twenty-eight individuals were ex-
amined in family SAL-612, and paraclinical investiga-
tions were performed in the index case (individual III:
4; see fig. 1), showing normal results for cerebral and
cervical imaging, conduction velocities and electromy-
ography of the lower limbs, fundoscopy, and evoked
visual potentials. Disability was assessed on a three-
point scale: 1= normal gait or very light stiffness of the
legs, 2 = inability to run, and 3 = either inability to walk
without help or confinement to a wheelchair (table 1).
A severity score related to disease duration was obtained
by dividing the disability score by disease duration (in
years) and multiplying the result by 100 (table 1). To
compare the clinical features of family SAL-612 and
SPG4-linked families, the following statistical tests were
used: t-test, for comparison of means, and x2 test, for
frequencies (with Yates’s correction, if necessary).
Blood samples were collected from all consenting in-
dividuals, and DNAwas prepared according to standard
methods. Primers for dinucleotide repeats used in this
study, as well as their location on genetic maps, were as
described by Dib et al. (1996). In addition, the following
markers were used for testing: D14S1055, D14S269,
D14S1031, and D14S978, for SPG3 (Hazan et al. 1993);
D2S2325, D2S2351, D2S2347, and D2S352, for SPG4
(Hazan et al. 1994); D15S1021, D15S1002, and
D15S122, for SPG6 (Fink et al. 1995); and D8S1793,
D8S1799, and D8S1832, for SPG8 (Hedera et al. 1999).
PCRs were performed with fluorescently labeled primers
(6-FAM, HEX, and TET), as recommended by the sup-
plier. Amplification products were then pooled, loaded
onto a 6% acrylamide denaturing gel on an ABI 377
DNA sequencer (PE Biosystems), and analyzed by GE-
NESCAN version 2.1.1 and GENOTYPER version 1.1.1
softwares.
Pairwise and multipoint LOD scores were calculated
by use of the MLINK and LINKMAP programs of the
LINKAGE package. A disease-allele frequency of .0001
was assumed. Only affected individuals who had been
clinically tested by one of us were considered as affected
for purposes of the LOD-score calculations. Patient II:
5 in family SAL-612, who, on the basis of her medical
history, was considered to be affected was, for purposes
of the LOD-score calculations, considered as being of
undetermined clinical status, since she was never ex-
amined by one of us. Individual III:5, who was 50 years
old and had increased and spread reflexes in the lower
limbs and an extensor plantar response (by Babinski
sign) but no spasticity, also was, for purposes of the
LOD-score calculations, considered as being of unde-
termined clinical status (fig. 1). Since penetrance of au-
tosomal dominant HSP is a function of age, liability
classes as described elsewhere (Du¨rr et al. 1996), as well
as a penetrance of .90, were used. No significant differ-
ences between the two models were noted. LOD scores
were calculated both with the assumption of equal allele
frequency and with allele frequencies determined in the
Centre d’E´tude du Polymorphisme Humain pedigrees.
Both methods gave similar results.
At the beginning of our study for autosomal dominant
HSP, we tested linkage between the disease segregating
in family SAL-612 and dinucleotide repeats at four
known loci (SPG3, SPG4, SPG6, and SPG8; reported by
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Figure 2 Genetic linkage to chromosome 2q24-q34 in family SAL-612. Multipoint LOD scores between chromosome 2q24-q34 markers
and HSP.
Hazan et al. [1993, 1994], Fink et al. [1995], andHedera
et al. [1999], respectively), and we observed negative
LOD scores, as well as obligate recombinants in patients,
at all four of these loci (data not shown). These results
indicated that the disease was not linked to any of these
loci in family SAL-612. We then performed a genome-
wide search, using 318 dinucleotide repeats evenly
spaced every 10–15 cM on the autosomes.
A maximum LOD score (Zmax) of 3.03 was observed
for marker D2S2318, at a recombination fraction of 0.
To test whether this positive LOD score resulted from
random association in a relatively small kindred or
from true linkage, 25 markers spaced every 1–5 cMwere
further tested, and the haplotype segregating with the
disease was constructed. A selection of 11 markers is
shown in figure 1. Multipoint linkage analysis using
markers D2S335, D2S2314, D2S364, D2S118, D2S117,
D2S2318, D2S2392, and D2S309 gave a Zmax of 3.43
at microsatellite D2S2392 (fig. 2). Construction of the
haplotype segregating with the disease showed that all
markers flanked by D2S2195 and D2S309 cosegregated
with the disease (fig. 1). In family SAL-612, individuals
who carried the disease haplotype but who were normal
on the basis of neurological examination were noted:
unaffected individuals III:10, IV:1, and IV:2 (32, 31,
and 28 years old, respectively) were haplotype carriers
(fig. 1). To precisely delimit the locus by means of the
analysis of recombinants, we chose the most conserva-
tive method—that is, we considered recombinationsonly
in affected individuals. The centromeric boundary at
D2S2195 was defined by the recombination event de-
tected in patients III:1 and III:4 and transmitted to af-
fected offspring IV:5, whereas the telomeric boundary
at D2S309 was defined by the recombination event ob-
served in patient III:12 (fig. 1). These results demon-
strated the existence of a new HSP locus, which maps
to a 30-cM interval flanked by markers D2S2195 and
D2S309 on chromosome 2q24-q34.
Clinical data on family SAL-612 were used for com-
parison with clinical features of patients with SPG4 who
had been described elsewhere (Du¨rr et al. 1996). There
was no significant difference in the mean age at onset,
the presence of increased reflexes in the lower limbs,
decreased vibration sense, urinary urgency, or pes cavus
(table 1); however, Babinski signs were significantly less
frequent in family SAL-612 than in families with SPG4
(56% vs. 88%; ), but increased reflexes in theP ! .05
upper limbs (67% vs. 22%; ) and severe func-P ! .05
tional handicap (44% vs. 11%; ) were moreP ! .05
frequent.
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We have described a new locus for autosomal domi-
nant pure spastic paraplegia, a locus that maps to chro-
mosome 2q24-q34. In family SAL-612, the whole ge-
nome was screened, and only markers in the chro-
mosome 2q24-q34 region generated LOD scores over
the threshold of 3.00, which was confirmed by multi-
point linkage analysis. Moreover, the haplotype of this
chromosomal region was constructed and shown to seg-
regate with the disease. LOD scores were calculated con-
servatively; only clinically affected individuals examined
by one of us were considered as affected. These results
strongly support the hypothesis of true genetic linkage
and demonstrate the existence of a new locus for au-
tosomal dominant pure spastic paraplegia, on chro-
mosome 2q24-q34.
It is now well established that the penetrance of au-
tosomal dominant HSP is age dependant and incom-
plete. In families with linkage to SPG4, 30% of the gene
carriers are unaware of symptoms but are clinically af-
fected (Du¨rr et al. 1996). Three individuals in family
SAL-612 who were normal on the basis of neurological
examination but whose age at onset of the disease is
younger than the mean carry the disease haplotype. This
observation has important clinical implications for ge-
netic counseling in HSP: normal clinical examination is
not sufficient to establish a diagnosis; despite being nor-
mal on the basis of neurological examination, a person
may carry the disease haplotype—and thus may transmit
the disease.
Genotype-phenotype correlations are difficult to es-
tablish for autosomal dominant HSP, since most loci
have been identified in only a small number of families.
Elsewhere, we have suggested that the absence of sensory
signs might be a distinctive features of SPG3 (Hazan et
al. 1993; Fontaine et al. 1995). SPG4 is the only locus
for which clinical data could be collected from a large
number of families (Du¨rr et al. 1996; Fink et al. 1996).
We compared the clinical features of family SAL-612 to
those of 12 families with linkage to SPG4 (Du¨rr et al.
1996). The only significant differences were lack of Ba-
binski signs, increased reflexes in the upper limbs, and
a more severe handicap in family SAL-612. More-de-
tailed phenotype-genotype correlations will require col-
laborative studies, however, in order to assemble a suf-
ficient number of families linked to the same locus.
The gene for autosomal recessive symmetrical spastic
cerebral palsy has recently been mapped to chromosome
2q24-25 (McHale et al. 1999). Although the diseases
differ both in their clinical presentation and in their
mode of transmission, we cannot exclude the possibility
that they might represent allelic mutations of the same
gene. For example, both myotonia congenita of auto-
somal recessive inheritance and that of autosomal dom-
inant inheritance have been shown to be caused by mu-
tations in the same gene encoding the chloride channel
CLCN1 (Koch et al. 1992). Both autosomal recessive
symmetrical spastic cerebral palsy and autosomal dom-
inant pure spastic paraplegia mapping to chromosome
2q24-q34 affect the pyramidal tracts, and the two loci
overlap; indeed, considering the recombinations in fam-
ily SAL-612, we have shown that both loci overlap in
the 5-cM region flanked by D2S294 and D2S2195.
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